BioTelemetry, Inc. (BEAT) Hits New 1-Year High at $38.70
BioTelemetry, Inc. (NASDAQ:BEAT)’s share price reached a new 52-week high on Friday . The stock traded as high as $38.70 and last traded at $38.60, with a volume of 239,829 shares trading hands. The stock had previously closed at $37.60.
BEAT has been the subject of several recent research reports. Sidoti restated a “buy” rating and set a $49.00 target price (up from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Dougherty & Co raised their target price on shares of BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub downgraded shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Benchmark Co. raised their target price on shares of BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Finally, Lake Street Capital restated a “buy” rating and set a $50.00 target price (up from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. BioTelemetry has a consensus rating of “Buy” and a consensus price target of $44.40.
The company has a 50 day moving average price of $35.56 and a 200 day moving average price of $30.92. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of 25.91 and a beta of 0.73.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Tuesday, August 8th. The medical research company reported $0.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.02. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. The company had revenue of $58.10 million during the quarter, compared to the consensus estimate of $58.39 million. During the same period in the prior year, the company earned $0.20 EPS. BioTelemetry’s revenue was up 10.2% on a year-over-year basis. Analysts predict that BioTelemetry, Inc. will post $0.99 EPS for the current year.
A number of hedge funds have recently bought and sold shares of the business. Piedmont Investment Advisors LLC purchased a new stake in BioTelemetry during the second quarter valued at about $207,000. Castleark Management LLC purchased a new stake in BioTelemetry during the second quarter valued at about $11,806,000. Raymond James Financial Services Advisors Inc. purchased a new stake in BioTelemetry during the second quarter valued at about $212,000. The Manufacturers Life Insurance Company lifted its stake in BioTelemetry by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 21,949 shares of the medical research company’s stock valued at $734,000 after buying an additional 763 shares in the last quarter. Finally, State Street Corp lifted its stake in BioTelemetry by 2.5% during the second quarter. State Street Corp now owns 756,298 shares of the medical research company’s stock valued at $25,297,000 after buying an additional 18,500 shares in the last quarter. 77.99% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/08/biotelemetry-inc-beat-hits-new-1-year-high-at-38-70.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.